DelveInsight’s, “Renal Cell Carcinoma Pipeline Insight, 2023,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in the Renal Cell Carcinoma pipeline landscape. It covers the Renal Cell
Renal Cell Carcinoma Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight
STEMart has recently introduced Bioburden Tissue Testing services for medical applications, including Aerobic Count, Anaerobic Count, Fungi/Mold Count, and Spore Count. New York, USA – January 23, 2023 – STEMart,
DelveInsight’s ‘Refractory Multiple Myeloma Pipeline Insight 2022’ report provides comprehensive global coverage of available, marketed, and pipeline refractory multiple myeloma therapies in various stages of clinical development, major pharmaceutical companies
CD BioSciences recently launched a comprehensive panel of research solutions covering all aspects of cell death studies. New York, USA – January 23, 2023 – CD BioSciences, a US-based CRO
DelveInsight’s, “Prostate Cancer Pipeline Insight, 2022,” report provides comprehensive insights about 200+ companies and 200+ pipeline drugs in Prostate Cancer
CD BioSciences has recently announced the launch of scaffold-based technologies to assist researchers in achieving organotypic co-culture and simulating layered
DelveInsight’s, “Pancreatic Ductal Adenocarcinoma Pipeline Insight, 2022,” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the
Updapt, a SaaS based ESG Solution Co., announced today that Mr. Erik Solheim, a Green Leader and Norwegian Diplomat, has
DelveInsight’s, “Pancreatic Cancer Pipeline Insight, 2023,” report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Pancreatic Cancer
DelveInsight’s, “Ovarian Cancer Pipeline Insight, 2022,” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Ovarian
